Dr. Peter Teng, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 523 E 25th St, Hialeah, FL 33013 Phone: 305-696-5088 Fax: 305-696-5063 |
Mr. Jaime Garcia, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 935 W 49th St, Suite 107, Hialeah, FL 33012 Phone: 305-827-2268 Fax: 305-828-1533 |
Don S. Shalhub, M.D. Dermatology - Procedural Dermatology Medicare: Accepting Medicare Assignments Practice Location: 7100 W. 20th Avenue, S. 414, Hialeah, FL 33016 Phone: 305-557-3311 Fax: 305-444-3530 |
Avelino A Guiribitey, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 4445 W 16th Ave Ste 300, Hialeah, FL 33012 Phone: 305-826-5887 Fax: 305-362-1559 |
Mr. Gonzalo Estevez Del Cristo, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 44 E 5th St, Hialeah, FL 33010 Phone: 305-888-9786 Fax: 305-888-8243 |
News Archive
Pregnant women living in areas with contaminated drinking water may be more likely to have babies that are premature or with low birth weights (considered less than 5.5 pounds), according to a study based at Princeton University's Woodrow Wilson School of Public and International Affairs.
A new study led by scientists at The Scripps Research Institute suggests that cells construct protein "clumps" to protect against neurodegenerative diseases such as amyotrophic lateral sclerosis, a.k.a. ALS or Lou Gehrig's disease.
Young women with premature ovarian insufficiency may be able to use their own bone marrow stem cells to rejuvenate their ovaries and avoid the effects of premature menopause, new research suggests.
G-Zero Therapeutics, an RTP company started in 2008 based on technologies from the University of North Carolina at Chapel Hill, has been awarded a $3 million Phase II Small Business Innovation Research Grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
4SC AG, the German drug discovery and development company, today announced the dosing of the first patient in its Phase II trial with 4SC-201 (resminostat), a pan-histone deacetylase (HDAC) inhibitor, as a new potential treatment option for patients with advanced hepatocellular carcinoma (HCC), the most frequent form of liver cancer.
› Verified 7 days ago